

## Conference Program

All sessions will take place in the Regency Ballroom unless otherwise noted.

### Monday, June 18

**7:30 p.m.-9:00 p.m.**                    **Keynote Presentations and Discussion:  
Pancreatic Cancer 2012 – Do We Have the Tools and  
Knowledge to Defeat It?**

**Welcome**

**7:30 p.m.**   **Fatal attraction: A new story featuring the immune system and pancreatic cancer**  
Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

**8:00 p.m.**   **The relentless pursuit approach**  
Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ

**8:30 p.m.**   **Discussion**

**9:00 p.m.-10:30 p.m.**                **Dessert Reception**

### Tuesday, June 19

**7:00 a.m.-8:00 a.m.**                    **Continental Breakfast and  
Meet-the-Expert Roundtable Session 1**  
*List of experts available at the registration desk*

**8:00 a.m.-10:00 a.m.            Session 1: Can We Diagnose Pancreatic Cancer Early?**  
*Session Chairperson: Michael G. Goggins, Johns Hopkins  
Medical Institutes, Baltimore, MD*

**8:00 a.m.    Characterization of pancreatic circulating tumor cells for novel biomarkers  
and therapeutic targets**  
David T. Ting, Massachusetts General Hospital Cancer Center, Boston, MA

**8:25 a.m.    A mouse to human search for pancreatic cancer markers**  
Samir M. Hanash, Fred Hutchinson Cancer Center, Seattle, WA

**8:50 a.m.    Molecular imaging and biomarker discovery in pancreatic cancer**  
Kimberly A. Kelly, University of Virginia, Charlottesville, VA

**9:15 a.m.    An engineered chimeric, Fc-mutated Anti-CA19-9 scFv-Fc for targeting  
pancreas cancer in an orthotopic model\***  
James S. Tomlinson, VHA Greater Los Angeles Medical Center, Los Angeles, CA

**9:30 a.m.    Panel Discussion**

**10:00 a.m.-10:30 a.m.            Break**

**10:30 a.m.-12:30 p.m.            Session 2: Can Pancreatic Cancer Be Avoided?**  
*Session Chairperson: Gloria M. Petersen, Mayo Clinic College  
of Medicine, Rochester, MN*

**10:30 a.m.    Obesity, autophagy and inflammation: Common features in the pathogenesis  
and etiology of liver and pancreatic cancers**  
Michael Karin, University of California, San Diego, CA

**10:55 a.m.    Pancreatic cancer: Identifying those at high risk**  
Alison P. Klein, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,  
Baltimore, MD

**11:20 a.m.    Familial pancreatic cancer surveillance: Outcomes and natural history of 100  
patients over a decade**  
Teresa A. Brentnall, University of Washington, Seattle, WA

**11:45 a.m.    Role of vitamin D receptor (VDR) gene polymorphisms for overall survival in  
pancreatic cancer: Genome-wide association and functional mechanistic  
studies\***  
Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC

**12:00 p.m.    Panel Discussion**

**12:30 p.m.-2:30 p.m.            Poster Session A and Lunch**  
*Lakeside Ballroom*

\*Short talks from proffered papers

- 2:30 p.m.-4:30 p.m.**                    **Session 3: How Does Pancreatic Cancer Develop?**  
*Session Chairperson: Steven D. Leach, Johns Hopkins University School of Medicine, Baltimore, MD*
- 2:30 p.m.**    **Genomic analysis reveals roles for chromatin modification and axon guidance in pancreatic cancer**  
Andrew V. Biankin, Garvan Institute of Medical Research, Sydney, Australia
- 2:55 p.m.**    **Using patient-derived xenografts for personalized medicine in pancreas cancer**  
Manuel Hidalgo, Spanish National Cancer Center, Madrid, Spain
- 3:20 p.m.**    **Loss of the chromatin regulator Brg1 affects neoplasia and pancreatic cancer formation**  
Matthias Hebrok, University of California, San Francisco, CA
- 3:45 p.m.**    **Association between ambient ultraviolet radiation at birth, skin type, skin cancer history, and pancreatic cancer\***  
Rachel E. Neale, Queensland Institute of Medical Research, Brisbane, Australia
- 4:00 p.m.**    **Panel Discussion**
- 4:30 p.m.-7:30 p.m.**                    **Dinner Break (Dinner on your own)**
- 7:30 p.m.-9:30 p.m.**                    **Session 4: Why Does Pancreatic Cancer Metastasize and Cause Cachexia and Pain?**  
*Session Chairperson: Michael A. Hollingsworth, University of Nebraska Medical Center Eppley Cancer Center, Omaha, NE*
- 7:30 p.m.**    **EMT and dissemination precede pancreatic tumor formation**  
Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
- 7:55 p.m.**    **The role of pancreatic cancer stem cells in metastasis**  
Zeshaan A. Rasheed, Johns Hopkins University School of Medicine, Baltimore, MD
- 8:20 p.m.**    **Cachexia, immune suppression, and the FAP+ stromal cell**  
Douglas Fearon, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
- 8:45 p.m.**    **Neuroplastic changes and pain-related behavior in a transgenic mouse model of pancreatic ductal adenocarcinoma (PDAC)\***  
Rachelle E. Stopczynski, University of Pittsburgh, Pittsburgh, PA
- 9:00 p.m.**    **Panel Discussion**

\*Short talks from proffered papers

## Wednesday, June 20

- 7:00 a.m.-8:00 a.m.**      **Continental Breakfast and Meet-the-Expert Roundtable Session 2**  
*List of experts available at the registration desk*
- 8:00 a.m.-10:00 a.m.**      **Session 5: How Does the Tumor Microenvironment Influence Pancreatic Cancer?**  
*Session Chairperson: Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA*
- 8:00 a.m.**    **Dynamic and reciprocal force regulation of tumor progression**  
Valerie M. Weaver, University of California San Francisco Medical Center, San Francisco, CA
- 8:25 a.m.**    **Inflammation and cancer: Reprogramming the immune microenvironment as an anticancer therapeutic strategy**  
Lisa M. Coussens, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR
- 8:50 a.m.**    **Immune surveillance and CD40 therapy of pancreatic cancer in mice and humans**  
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
- 9:15 a.m.**    **Macropinocytosis as a mechanism of amino acid supply\***  
Cosimo Commisso, New York University School of Medicine, New York, NY
- 9:30 a.m.**    **Panel Discussion**
- 10:00 a.m.-10:30 a.m.**      **Break**

\*Short talks from proffered papers

- 10:30 a.m.-12:30 p.m.      Session 6: Can KRAS Be Defeated?**  
*Session Chairperson: Channing J. Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC*
- 10:30 a.m. Targeting K-Ras for the treatment of pancreatic cancer**  
 Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN
- 10:55 a.m. Functional genomics and KRAS-driven cancers**  
 William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
- 11:20 a.m. Targeting unique dependencies of RAS mutant tumors**  
 Julian Downward, Cancer Research UK London Research Institute, London, United Kingdom
- 11:45 a.m. Oncogenic Ras requires stimulation for activity sufficient to initiate a feed-forward inflammatory mechanism capable of inducing pancreatic diseases, including pancreatitis and cancer\***  
 Craig D. Logsdon, The University of Texas MD Anderson Cancer Center, Houston, TX
- 12:00 p.m. Panel Discussion**
- 12:30 p.m.-2:30 p.m.      Poster Session B and Lunch**  
*Lakeside Ballroom*
- 2:30 p.m.-4:30 p.m.      Session 7: What Are the Promising Preclinical and Clinical Advances in Pancreatic Cancer?**  
*Session Chairperson: Margaret A. Tempero, University of California, San Francisco, CA*
- 2:30 p.m. Targeting cancer stem cells in pancreatic cancer**  
 Diane M. Simeone, University of Michigan Hospital and Health Systems, Ann Arbor, MI
- 2:55 p.m. Altering drug delivery in pancreatic cancer: Development and clinical translation of smoothed inhibitors**  
 Kenneth P. Olive, Columbia University Irving Comprehensive Cancer Center, New York, NY
- 3:20 p.m. How much gemcitabine reaches the target... and does it matter?**  
 Duncan I. Jodrell, Cambridge University, Cambridge, United Kingdom
- 3:45 p.m. Clonal profiling of prospectively collected primary pancreatic ductal adenocarcinomas\***  
 Michael T. Barrett, Translational Genomics Research Institute, Scottsdale, AZ
- 4:00 p.m. Panel Discussion**

\*Short talks from proffered papers

- 4:30 p.m.-5:00 p.m. Break**
- 5:00 p.m.-7:00 p.m. Session 8: Are There New Ways to Prevent or Treat Pancreatic Cancer?**  
*Session Chairperson: Anil K. Rustgi, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA*
- 5:00 p.m. Autophagy, metabolism, and pancreatic cancer**  
Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA
- 5:25 p.m. Regulation of metabolism to support tumor growth**  
Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
- 5:50 p.m. Microenvironment and pancreatic cancer**  
Roland M. Schmid, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany
- 6:15 p.m. Targeted therapy for pancreatic cancer\***  
Sanjay Awasthi, Beckman Research Institute, City of Hope, Duarte, CA
- 6:30 p.m. Panel Discussion**
- 7:00 p.m.-8:30 p.m. Buffet Dinner**  
*Lakeside Ballroom*
- 8:30 p.m.-10:00 p.m. Keynote Presentations and Discussion: Progress Ahead for Pancreatic Cancer**
- 8:30 p.m. Targeting KRAS directly**  
Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
- 9:00 p.m. Kras-directed anabolic processes in PDAC tumor maintenance**  
Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX
- 9:30 p.m. Discussion**
- Closing Remarks**

**Thursday, June 21**

**Departure**